Celadon Pharmaceuticals Plc

LSE CEL.L

Celadon Pharmaceuticals Plc Total Non-Current Liabilities for the year ending December 31, 2023: USD 6.47 M

Celadon Pharmaceuticals Plc Total Non-Current Liabilities is USD 6.47 M for the year ending December 31, 2023, a 6.70% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Celadon Pharmaceuticals Plc Total Non-Current Liabilities for the year ending December 31, 2022 was USD 6.06 M, a 21,973.42% change year over year.
Celadon Pharmaceuticals Plc Total Non-Current Liabilities for the year ending December 31, 2021 was USD 27.47 K, a -99.31% change year over year.
Celadon Pharmaceuticals Plc Total Non-Current Liabilities for the year ending December 31, 2020 was USD 3.98 M.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

LSE: CEL.L

Celadon Pharmaceuticals Plc

CEO	Mr. James Gareth Short
IPO Date	March 31, 2022
Location	United Kingdom
Headquarters	32-33 Cowcross Street
Employees	27
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Tobacco

Description

Celadon Pharmaceuticals Plc, a pharmaceutical company, engages in the research, manufacture, and supply of cannabinoids for use in approved medicines. The company focuses on growing indoor hydroponic THC cannabis for use in medicinal products used to treat chronic pain. It also intends to conduct research into cannabinoids for use in chronic pain, as well as other conditions, such as autism and multiple sclerosis. The company was founded in 2018 and is headquartered in London, the United Kingdom.

Key trends

Past 5 years